“PromarkerD will save lives and healthcare costs” – Dr Richard Lipscombe to American Diabetes Association (ADA) TV
To develop PromarkerD, Proteomics International used the Promarker™ platform to identifiy a panel of novel protein markers (biomarkers) that are significantly effective in diagnosing and predicting diabetic kidney disease. The PromarkerD test measures the concentration of these biomarkers to diagnose and predict a person’s risk of developing diabetic kidney disease.
The ability of the biomarkers to diagnose and predict diabetic kidney disease was studied and verified in three clinical studies. The results of these studies have been published and presented at events around the world..